Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
- NCT01371981
- NCI-2011-02670, COG-AAML1031, CDR0000701850, AAML1031, U10CA098543
Trial sponsor
National Cancer Institute (NCI)
Scientific Title
A Phase III Randomized Trial for Patients With de Novo AML Using Bortezomib and Sorafenib for Patients With High Allelic Ratio FLT3/ITD